Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
113.50    0.00 (0.00%)
Bid:
110.00
Ask:
117.00
Spread: 7.00 (6.364%)
Market Cap: £15.31m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Full Year Trading Update

13 Jan 2026 07:00

RNS Number : 5928O
Itaconix PLC
13 January 2026
 

For release: 07.00, 13 January 2026

Itaconix plc

("Itaconix" or the "Company")

Full Year Trading Update

Record revenues exceeding $10 million for the first time, driven by third consecutive record half year and strong customer momentum

Itaconix plc (AIM: ITX) (OTCQB: ITXXF), a leading innovator in high-performance plant-based specialty polymers, is pleased to provide a trading update for the year ended 31 December 2025.

Unaudited revenues for FY 2025 increased 59% year-on-year to $10.3 million (FY 2024: $6.5 million), exceeding $10 million for the first time. This performance was underpinned by a third consecutive record half year, with revenues of $5.5 million in H2 2025, up from $4.8 million in H2 2024.

Revenue growth was generated across both existing and new customers, spanning major applications and geographies. Demand for the Company's patented plant-based polymers continued to strengthen as global consumer product manufacturers increasingly adopt sustainable, high-performance ingredients to enhance formulation performance and deliver added value in detergent, hygiene and beauty products. This growth in revenue and a step change in the Company's commercial traction have enabled Itaconix to invest further in demand generation and support for 2026.

The Board remains optimistic about the Company's prospects for 2026 and believes that Itaconix is well positioned to deliver continued revenue growth, supported by a growing customer pipeline, expanding product adoption and a scalable, capital-efficient operating model. 

Further details on 2025 trading performance and the outlook for 2026 will be provided with the Company's FY 2025 results, expected in late March 2026.

John R. Shaw, CEO of Itaconix, commented:

"2025 was a milestone year for Itaconix. Delivering record revenues of over $10 million for the first time, alongside our third consecutive record half year, demonstrates the accelerating commercial momentum behind our technology and customer proposition.

"We are seeing growing validation from both new and existing customers as our plant-based specialty polymers become embedded in next-generation consumer products where performance, sustainability and value are all critical.

"Entering 2026, Itaconix is operating from a position of strength: we are well funded, capital efficient and supported by a deep and expanding revenue pipeline. With increasing scale, disciplined execution and strong customer engagement, we believe the Company is firmly on track towards building a large, profitable and enduring specialty ingredients business, delivering long-term value for shareholders."

- ends -

Enquiries:

Itaconix plc +1 603 775 4400

John R. Shaw / Laura Denner

Rosewood +44 (0) 207 653 8704

Financial PR

John West / Llewellyn Angus / Lily Pearce

Canaccord Genuity +44 (0) 7523 8000

Nominated Adviser and Broker

Adam James / Harry Pardoe

 

About Itaconix

Itaconix uses its proprietary plant-based polymer technology platform to produce and sell specialty ingredients that improve the safety, performance, and sustainability of consumer products. The Company's current ingredients are enabling and leading new generations of cost-effective, decarbonized consumer products in home and personal care.

www.itaconix.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBIGDBXBBDGLD
Date   Source Headline
5th Sep 20237:00 amRNSNotice of Interim Results and Presentations
22nd Aug 20237:00 amRNSShare Consolidation & Total Voting Rights
15th Aug 20237:00 amRNSShare Consolidation
12th Jul 20237:00 amRNSTrading Update
28th Jun 202312:29 pmRNSAGM Statement
5th Jun 20237:00 amRNSFinal Results
24th May 20237:00 amRNSNotice of Final Results, Briefings, and AGM
25th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
2nd Mar 20233:25 pmRNSTR-1
1st Mar 20237:00 amRNSAward from Frost & Sullivan
28th Feb 20236:03 pmRNSTR-1
28th Feb 20235:04 pmRNSTR-1
28th Feb 20233:09 pmRNSTR-1
23rd Feb 20237:00 amRNSTR-1
22nd Feb 202312:28 pmRNSResults of Open Offer, GM and Total Voting Rights
15th Feb 20237:00 amRNSInvestor Presentation following GM on 22 Feb 2023
3rd Feb 20237:00 amRNSPlacing, Subscription and Open Offer; Notice of GM
5th Jan 20237:00 amRNSBoard Change
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSItaconix and Brenntag Promote Sustainable Cleaning
14th Sep 20227:00 amRNSHalf year results
13th Sep 202211:05 amRNSSecond Price Monitoring Extn
13th Sep 202211:00 amRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSNotice of Results
5th Sep 20227:00 amRNSItaconix and Croda Renew Supply Agreement
20th Jul 20227:00 amRNSBoard Change
13th Jul 20227:00 amRNSTrading Update
5th Jul 20227:00 amRNSDirectorate Change
1st Jul 20222:37 pmRNSResult of AGM
1st Jul 20229:00 amRNSPrice Monitoring Extension
1st Jul 20227:00 amRNSAGM Statement and Notice of Capital Markets Event
29th Jun 20227:00 amRNSNotice of Capital Markets Webinar
8th Jun 20229:04 amRNSFinal Results - replacement
8th Jun 20227:30 amRNSTR-1
8th Jun 20227:00 amRNSFinal Results
6th Jun 20222:00 pmRNSPrice Monitoring Extension
27th May 20227:00 amRNSNotice of Final Results, Presentation and AGM
22nd Apr 20227:00 amRNSNew Funding to Support EU Volumes
20th Apr 20227:00 amRNSTrading Update
19th Apr 20227:00 amRNSBoard Changes
29th Mar 202211:05 amRNSSecond Price Monitoring Extn
29th Mar 202211:00 amRNSPrice Monitoring Extension
22nd Feb 20224:41 pmRNSSecond Price Monitoring Extn
22nd Feb 20224:35 pmRNSPrice Monitoring Extension
16th Feb 20224:41 pmRNSSecond Price Monitoring Extn
16th Feb 20224:36 pmRNSPrice Monitoring Extension
16th Feb 20227:00 amRNSInvestor Event
9th Feb 202211:06 amRNSSecond Price Monitoring Extn
9th Feb 202211:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.